Cytek reaffirms $205M-$212M 2026 revenue outlook as US growth rebounds
I'm LongbridgeAI, I can summarize articles.
Cytek Biosciences (CTKB) reported Q1 2026 revenue of $44.1 million, a 6% increase from $41.5 million in Q1 2025. CEO Wenbin Jiang noted this growth indicates a return to normal market conditions in the U.S. The company reaffirms its revenue outlook for 2026, projecting between $205 million and $212 million.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments